Advances in Understanding Autism Spectrum Disorder

Luigi Mazzone; Leonardo Emberti Gialloreti; Paolo Curatolo

doi:10.1055/s-0037-1602814

Journal of Pediatric Neurology, Table of Contents

Journal of Pediatric Neurology 2017; 15(03): 096-098
DOI: 10.1055/s-0037-1602814

Review Article

Georg Thieme Verlag KG Stuttgart · New York

Advances in Understanding Autism Spectrum Disorder

Luigi Mazzone

¹Child Neurology and Psychiatry Unit, System Medicine Department, Tor Vergata, University Hospital of Rome, Italy

²Department of Neuroscience and Neurorehabilitation, Bambino, Gesù Children's Hospital, IRCCS, Rome, Italy

,

Leonardo Emberti Gialloreti

³Centre for Communication and Neurorehabilitation Research, CNAPP, Rome, Italy

⁴Department of Biomedicine and Prevention, University of Rome, Tor Vergata, Italy

,

Paolo Curatolo

¹Child Neurology and Psychiatry Unit, System Medicine Department, Tor Vergata, University Hospital of Rome, Italy

› Author Affiliations

Abstract

Autism spectrum disorder (ASD) appears to have a dramatic increase over the last twenty years and according to the latest estimates, 1 out of 68 children has been diagnosed with this disorder. In this context, it is crucial to provide clinicians with the most updated information on the genetic, epigenetic, and environmental understanding of ASD, as well as to provide the best scientific evidence in order to build successful therapeutic strategies for the patients.

Keywords

autism spectrum disorder - genetics - environmental factors - treatment

Full Text

References

References
1 Dawson G, Rogers S, Munson J. , et al. Randomized, controlled trial of an intervention for toddlers with autism: the Early Start Denver Model. Pediatrics 2010; 125 (01) e17-e23
2 Reichow B, Barton EE, Boyd BA, Hume K. Early intensive behavioral intervention (EIBI) for young children with autism spectrum disorders (ASD). Cochrane Database Syst Rev 2012; 10: CD009260 . Doi: 10.1002/14651858.CD009260.pub2
3 Geschwind DH, Levitt P. Autism spectrum disorders: developmental disconnection syndromes. Curr Opin Neurobiol 2007; 17 (01) 103-111
4 Whitehouse AJ, Stanley FJ. Is autism one or multiple disorders?. Med J Aust 2013; 198 (06) 302-303
5 U.S. Department of Health and Human Services. Centers for Disease Control and Prevention. Prevalence of Autism Spectrum Disorder Among Children Aged 8 Years — Autism and Developmental Disabilities Monitoring Network, 11 Sites, United States, 2010. Morbidity and Mortality Weekly Report. Surveillance Summaries/Vol.63/No.2,March 28, 2014 Available at: http://www.cdc.gov/mmwr/pdf/ss/ss6302.pdf
6 Zoghbi HY. Postnatal neurodevelopmental disorders: meeting at the synapse?. Science 2003; 302 (5646): 826-830
7 Persico AM, Bourgeron T. Searching for ways out of the autism maze: genetic, epigenetic and environmental clues. Trends Neurosci 2006; 29 (07) 349-358
8 Abrahams BS, Geschwind DH. Advances in autism genetics: on the threshold of a new neurobiology. Nat Rev Genet 2008; 9 (05) 341-355
9 Geschwind DH, State MW. Gene hunting in autism spectrum disorder: on the path to precision medicine. Lancet Neurol 2015; 14 (11) 1109-1120
10 Benvenuto A, Manzi B, Alessandrelli R, Galasso C, Curatolo P. Recent advances in the pathogenesis of syndromic autisms. Int J Pediatr 2009; 2009: 198736 . Doi: 10.1155/2009/198736
11 Vorstman JA, Spooren W, Persico AM. , et al. Using genetic findings in autism for the development of new pharmaceutical compounds. Psychopharmacology (Berl) 2014; 231 (06) 1063-1078
12 Curatolo P, Napolioni V, Moavero R. Autism spectrum disorders in tuberous sclerosis: pathogenetic pathways and implications for treatment. J Child Neurol 2010; 25 (07) 873-880
13 Zhou J, Parada LF. PTEN signaling in autism spectrum disorders. Curr Opin Neurobiol 2012; 22 (05) 873-879
14 Walsh KS, Vélez JI, Kardel PG. , et al. Symptomatology of autism spectrum disorder in a population with neurofibromatosis type 1. Dev Med Child Neurol 2013; 55 (02) 131-138
15 Ehninger D. From genes to cognition in tuberous sclerosis: implications for mTOR inhibitor-based treatment approaches. Neuropharmacology 2013; 68: 97-105
16 Ma XM, Blenis J. Molecular mechanisms of mTOR-mediated translational control. Nat Rev Mol Cell Biol 2009; 10 (05) 307-318
17 Bauman ML, Kemper TL. Neuroanatomic observations of the brain in autism: a review and future directions. Int J Dev Neurosci 2005; 23 (2-3): 183-187
18 Coury DL, Anagnostou E, Manning-Courtney P. , et al. Use of psychotropic medication in children and adolescents with autism spectrum disorders. Pediatrics 2012; 130 (Suppl. 02) S69-S76
19 Scahill L, McCracken JT, King BH. , et al; Research Units on Pediatric Psychopharmacology Autism Network. Extended-release guanfacine for hyperactivity in children with autism spectrum disorder. Am J Psychiatry 2015; 172 (12) 1197-1206
20 Volkmar F, Siegel M, Woodbury-Smith M, King B, McCracken J, State M. ; American Academy of Child and Adolescent Psychiatry (AACAP) Committee on Quality Issues (CQI). Practice parameter for the assessment and treatment of children and adolescents with autism spectrum disorder. J Am Acad Child Adolesc Psychiatry 2014; 53 (02) 237-257
21 Rogers S, Wallace K. Intervention for infants and toddlers with autism spectrum disorders. . In: Amaral DG, Dawson G, Geschwind DH. , eds. Autism Spectrum Disorders. NewYork: Oxford University Press; 2011: 1081-1094
22 Howlin P, Charman T. Autism spectrum disorders, interventions and outcomes. . In: Howlin P, Charman T, Ghaziuddin M. , eds. The SAGE Handbook of Developmental Disorders. London: SAGE; 2011: 309-326
23 Howlin P, Magiati I, Charman T. Systematic review of early intensive behavioral interventions for children with autism. Am J Intellect Dev Disabil 2009; 114 (01) 23-41